SCHEMBL733042

SCHEMBL733042

CCOc1cc(C(=O)N2CCC3(CC2)CC(=O)c2cc(Nc4ccnn4C)ccc2O3)cc(-c2nnn[nH]2)c1.[NaH]

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.49
EPHX2 P34913 1/20 0.49
CACNA1C Q13936 1/20 0.49
ACACB O00763 8/20 0.41
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CASP1 P29466 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
ACACA Q13085 1/20 0.39
GLA P06280 2/20 0.38
THRB P10828 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15163403 0.99 CYP2C9 (0.50) CYP2C9EPHX2CACNA1CACACBALDH1A1
SCHEMBL733043 0.99 CYP2C9 (0.49) CYP2C9EPHX2CACNA1CACACBALDH1A1
SCHEMBL741027 0.90 EPHX2 (0.51) CYP2C9EPHX2CACNA1CACACBALDH1A1
SCHEMBL732918 0.87 EPHX2 (0.51) CYP2C9EPHX2CACNA1CACACBACACA
SCHEMBL730331 0.83 EPHX2 (0.56) CYP2C9EPHX2CACNA1CACACBACACA
SCHEMBL4422498 0.80 CYP2C9 (0.35) CYP2C9EPHX2CACNA1C
SCHEMBL733069 0.79 EPHX2 (0.49) CYP2C9EPHX2CACNA1CACACBACACA
SCHEMBL741033 0.76 EPHX2 (0.51) CYP2C9EPHX2CACNA1CACACBALDH1A1
SCHEMBL731187 0.75 ACACB (0.49) ACACBKMT2AACACA
SCHEMBL308867 0.75 EPHX2 (0.71) CYP2C9EPHX2CACNA1CALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP claimed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US claimed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP claimed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US claimed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO claimed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 CYP2C9 788/4885EPHX2 2301/4885CACNA1C 2444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.